
IndraLab
Statements
Bortezomib inhibits NFKBIA. 46 / 47
|
3
43
reach
"Many studies have demonstrated that bortezomib prevented IkappaBalpha from degradation by proteasome, thus inhibiting nuclear translocation of NF-kappaB, cytokine circuits and the survival advantage for MM cells conferred by the BM microenvironment [XREF_BIBR, XREF_BIBR, XREF_BIBR]."
reach
"The proteosomal inhibitor, bortezomib, suppresses NF-kappaB signaling by preventing IkappaBalpha degradation and is reported to reduce synovial macrophage inflammatory activity in experimental murine collagen arthritis [XREF_BIBR] but, again, is not specifically targeted to the macrophage."
reach
"In line with our observations, another study demonstrated differential effects of bortezomib on NFkappaB activity depending on different cell types : bortezomib triggered NFkappaB activity via the canonical pathway in peripheral blood mononuclear cells by enhancing non proteosomal degradation of IkappaBalpha while NFkappaB activation was inhibited in bone marrow derived stromal cells [39]."
reach
"As reported by many clinical trials, bortezomib alone or in combination with other drugs has dramatically improved the outcomes for patients with relapsed MM, which was in accordance with experimental results showing that bortezomib inhibited NF-kappaB activation in MM cells by blocking IkappaBalpha degradation in the proteasome."
reach
"The observation that bortezomib reduced IkB-alpha levels in human glioma cells is novel and, these findings are consistent with previous studies demonstrating that PS-341 as well other proteasome inhibitors induce IkB-alpha degradation in endometrial carcinoma cell lines, HepG2 liver cancer cell line, multiple myeloma cells and other tumor types."